SCHEMBL16636407

SCHEMBL16636407

COC(=O)[C@@H]1CCCC[C@H]1c1nc(-c2ccc(F)cc2)sc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 1/20 0.45
CTSK P43235 1/20 0.42
CNR2 P34972 6/20 0.37
CNR1 P21554 4/20 0.37
ABHD12 Q8N2K0 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
TRPV1 Q8NER1 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636408 1.00 SLC6A2 (0.45) SLC6A2SLC6A4CTSKCNR2CNR1
SCHEMBL16635827 0.86 CTSK (0.42) CTSKTRPM8NPC1RAB9ATRPV1
SCHEMBL16635678 0.86 CTSK (0.42) CTSKTRPM8NPC1RAB9ATRPV1
SCHEMBL16635592 0.79 CTSK (0.45) SLC6A2SLC6A4CTSKNPC1RAB9A
SCHEMBL16636350 0.78 SLC6A2 (0.45) SLC6A2SLC6A4CTSKNPC1RAB9A
SCHEMBL16636352 0.78 SLC6A2 (0.45) SLC6A2SLC6A4CTSKNPC1RAB9A
SCHEMBL16635754 0.78 CTSK (0.67) CTSK
SCHEMBL16635781 0.78 SLC6A2 (0.46) SLC6A2SLC6A4
SCHEMBL16635783 0.78 SLC6A2 (0.46) SLC6A2SLC6A4
SCHEMBL16635759 0.78 SLC6A2 (0.41) SLC6A2SLC6A4CNR2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A2 4308/4885SLC6A4 4386/4885CTSK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.